Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00499707 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 453
- Enrollment target
NCT00499707 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 453 participants.
The verdict
NCT00499707, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 453 participants
- Enrollment target
Study Summary
The purpose of this 32 week study is to demonstrate that fixed-dose combination treatment with rosiglitazone/metformin will safely and effectively control glycemia as first line oral therapy in subjects type 2 diabetes. The primary objective of the study is to demonstrate superiority of rosiglitazone/metformin compared to its rosiglitazone and metformin.
Interventions
- DRUG rosiglitazone maleate/metformin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 453 participants |
| Start Date | 2003-10-08 |
| Est. Completion | 2004-12-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00499707
The ClinicalTrials.gov registry entry for NCT00499707 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 453 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rosiglitazone maleate/metformin hydrochloride is the first listed.
NCT00499707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00499707 about?
NCT00499707 is a clinical study titled "Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects". The purpose of this 32 week study is to demonstrate that fixed-dose combination treatment with rosiglitazone/metformin will safely and effectively control glycemia as first line oral therapy in subjects type 2 diabetes. The primary objective of the study is to demonstrate superiority of rosiglitazon...
What is the current status of trial NCT00499707?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 453 participants. The study started on 2003-10-08. Estimated completion is 2004-12-16.
What interventions are being tested in trial NCT00499707?
The interventions under investigation include: rosiglitazone maleate/metformin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00499707?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.